Odds ratios of gallstone risk in SS subjects
UGT1A1 genotype . | SS clinic sample . | 95% CI . | SS cohort sample . | 95% CI . |
|---|---|---|---|---|
| 6/6 | 1.0 | — | 1.0 | — |
| 6/7 | 2.1 | 0.78-5.62 | 1.4 | 0.67-2.92 |
| 7/7 | 11.3 | 4.30-29.4* | 1.4 | 0.64-3.49 |
| 7/8 | 6.7 | 1.84-24.6† | 9.7 | 1.06-88.7† |
UGT1A1 genotype . | SS clinic sample . | 95% CI . | SS cohort sample . | 95% CI . |
|---|---|---|---|---|
| 6/6 | 1.0 | — | 1.0 | — |
| 6/7 | 2.1 | 0.78-5.62 | 1.4 | 0.67-2.92 |
| 7/7 | 11.3 | 4.30-29.4* | 1.4 | 0.64-3.49 |
| 7/8 | 6.7 | 1.84-24.6† | 9.7 | 1.06-88.7† |
Odds ratios and 95% CI for gallstone risk among subjects with symptoms (clinic sample) or for developing gallstones (cohort sample) by UGT1A1 (TA)n compared with the 6/6 wild type. P < .001 was regarded as significant after correction for multiple testing. — indicates not calculated.
P = 7 × 10-4.
P = .005 (clinic sample) or P = .03 (cohort sample).